Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 5, 2015, Pages 465-469

  El Eter, E ^a,b   Al Masri, A A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cardiovascular risk factors; Oxidative stress; Peroxiredoxins; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; OXYGEN RADICAL; PEROXIREDOXIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; ISOENZYME; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; AGED; ANALYSIS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; GLUCOSE BLOOD LEVEL; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ISOENZYMES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84930009758     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20144142     Document Type: Article

References (27)

1. Antoniades C, Antonopoulos AS, Bendall JK, Channon KM. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des 2009; 15: 329-342, doi: 10.2174/138161209787354230
2. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 2009; 46: 241-281, doi: 10.3109/10408360903142326
3. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47, doi: 10.1161/01.CIR.102.1.42
4. Ryden I, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetics, pre-diabetics, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (ESAD). Eur Heart J 2013; 34: 3035-3087, doi: 10.1093/eurheartj/eht108
5. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic BiolMed 2005; 38: 1543-1552, doi: 10.1016/j.freeradbiomed.2005.02.026
6. Jang HH, Lee KO, Chi YH, Jung BG, Park SK, Park JH, et al. Two enzymes in one; two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 2004; 117: 625-635, doi: 10.1016/j.cell.2004.05.002
7. Memisogullari R, Taysi S, Bakan E, Capoglu I. Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct 2003; 21: 291-296, doi: 10.1002/cbf.1025
8. Bhatia S, Shukla R, Venkata Madhu S, Kaur GJ, Madhava Prabhu K. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin Biochem 2003; 36: 557-562, doi: 10.1016/S0009-9120(03)00094-8
9. Kasznicki J, Kosmalski M, Sliwinska A, Mrowicka M, Stanczyk M, Majsterek I, et al. Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep 2012; 39: 8669-8678, doi: 10.1007/s11033-012-1722-9
10. El Eter E, Al Masri A, Habib S, Al Zamil H, Al Hersi A, Al Hussein F, et al. Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease. Cell Stress Chaperones 2014; 19: 173-181, doi: 10.1007/s12192-013-0442-y.
11. Al-Masri AA, El Eter E, Tayel S, Zamil H. Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 2014; 18: 710-716
12. Brinkmann C, Neumann E, Blossfeld J, Frese S, Orthmann P, Montiel G, et al. Influence of glycemic status and physical fitness on oxidative stress and the peroxiredoxin system in the erythrocytes of non-insulin-dependent type 2 diabetic men. Exp Clin Endocrinol Diabetes 2011; 119: 559-564, doi: 10.1055/s-0031-1279712
13. Savu O, Ionescu-Tirgoviste C, Atanasiu V, Gaman L, Papacocea R, Stoian I. Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetesmellitus. J Int Med Res 2012; 40: 709-716, doi: 10.1177/147323001204000235
14. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-756, doi: 10.1161/01.CIR.0000049640.46039.52
15. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54-B64
16. Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2011; 34: 34-38, doi: 10.2337/dc10-1420
17. Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011; 34: 665-673, doi: 10.1038/hr.2011.39
18. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-1320, doi: 10.1056/NEJMoa1107477
19. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56: e50-103, doi: 10.1016/j.jacc.2010.09001
20. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745, doi: 10.1001/jama.293.14.1737
21. Park S, Kim M, Paik JK, Jang YJ, Lee SH, Lee JH. Oxidative stress is associated with C-reactive protein in nondiabetic postmenopausal women, independent of obesity and insulin resistance. Clin Endocrinol 2013; 79: 65-70, doi: 10.1111/j.1365-2265.2012.04512.x.
22. Schulte J, Struck J, Kohrle J, Muller B. Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. Shock 2011; 35: 460-465, doi: 10.1097/SHK.0b013e3182115f40
23. Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA, et al. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ Res 2008; 103: 598-605, doi: 10.1161/CIRCRESAHA.108.174870
24. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc 2012; 1: e002956, doi: 10.1161/JAHA.112.002956
25. Chang JW, Lee SH, Lu Y, Yoo YJ. Transforming growth factor-beta1 induces the non-classical secretion of peroxiredoxin- I in A549 cells. Biochem Biophys Res Commun 2006; 345: 118-123, doi: 10.1016/j.bbrc.2006.04.073
26. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res 2011; 71: 1637-1646, doi: 10.1158/0008-5472.CAN-10-3674
27. Riddell JR, Wang XY, Minderman H, Gollnick SO. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol 2010; 184: 1022-1030, doi: 10.4049/jimmunol.0901945.